Company Quick10K Filing
Prevail Therapeutics
10-Q 2020-09-30 Filed 2020-11-13
10-Q 2020-06-30 Filed 2020-08-11
10-Q 2020-03-31 Filed 2020-05-14
10-K 2019-12-31 Filed 2020-03-26
10-Q 2019-09-30 Filed 2019-11-12
10-Q 2019-06-30 Filed 2019-08-14
S-1 2019-05-24 Public Filing
8-K 2020-11-13
8-K 2020-11-12
8-K 2020-11-02
8-K 2020-09-09
8-K 2020-08-11
8-K 2020-06-17
8-K 2020-05-14
8-K 2020-03-26
8-K 2020-03-02
8-K 2020-01-13
8-K 2020-01-09
8-K 2019-12-26
8-K 2019-11-15
8-K 2019-11-12
8-K 2019-10-08
8-K 2019-09-10
8-K 2019-08-15
8-K 2019-08-14
8-K 2019-06-24

Prevail Therapeutics Financials

PRVL Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
024 Pharma (EEIG)
11 Good Energy (ELVN)
1347 Capital Corp (TFSC)
Ameren Illinois Co (AILNP)
1PM Industries (OPMZ)
1st Century Bancshares (FCTY)
1st Financial Services Corp (FFIS)
1st United Bancorp (FUBC)
2-Track Global (TTG)
ENTERGY ARKANSAS, LLC (EAI)
21st Century Oncology Holdings (RTSX)
24Holdings (TWFH)
Bioquest Corp (BQST)
30DC (TDCH)
BriaCell Therapeutics Corp. (BCTXW)
DD3 Acquisition Corp. II (DDMXW)
3D Total Solutions (DTLS)
3DX Industries (DDDX)
8i Acquisition 2 Corp. (LAX)
ALABAMA POWER CO (APRCP)

Balance Sheet ($'000)2019-06-302019-09-30
Cash202,186183,165
Accounts Receivable
Inventory
PP&E2,2732,785
Assets216,078203,429
Accounts Payable2,0034,952
Long-Term Debt
Liabilities15,03921,401
Stockholders' Equity201,039182,028
Income Statement ($'000)2019-06-302019-09-30
Revenue
Cost of Revenue
Gross Profit
R&D11,95516,836
SG&A3,7134,452
Tax
Net Income-15,103-20,299
Cash Flow ($'000)2019-06-302019-09-30
Cash Operating-18,501
Cash Investing-512
Cash Financing-8